Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 10, 2021

SELL
$249.6 - $403.14 $329,721 - $532,547
-1,321 Closed
0 $0
Q4 2020

Feb 08, 2021

BUY
$221.31 - $316.61 $292,350 - $418,241
1,321 New
1,321 $341,000

Others Institutions Holding BGNE

About BeiGene, Ltd.


  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $21.4B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Bp PLC Portfolio

Follow Bp PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bp PLC, based on Form 13F filings with the SEC.

News

Stay updated on Bp PLC with notifications on news.